Brokers Set Expectations for LSTA Q2 Earnings

Lisata Therapeutics, Inc. (NASDAQ:LSTA) – Analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for shares of Lisata Therapeutics in a research report issued to clients and investors on Wednesday, June 18th. HC Wainwright analyst J. Pantginis anticipates that the company will earn ($0.66) per share for the quarter. The consensus estimate for Lisata Therapeutics’ current full-year earnings is ($2.66) per share. HC Wainwright also issued estimates for Lisata Therapeutics’ Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($2.79) EPS, FY2026 earnings at ($1.25) EPS, FY2027 earnings at ($1.33) EPS and FY2028 earnings at ($1.17) EPS.

Lisata Therapeutics Stock Up 0.4%

Shares of Lisata Therapeutics stock opened at $2.40 on Monday. Lisata Therapeutics has a 12-month low of $1.87 and a 12-month high of $4.20. The business’s 50 day moving average is $2.46 and its 200-day moving average is $2.58. The stock has a market cap of $20.69 million, a P/E ratio of -1.04 and a beta of 1.00.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.02).

Institutional Investors Weigh In On Lisata Therapeutics

An institutional investor recently raised its position in Lisata Therapeutics stock. Dimensional Fund Advisors LP boosted its holdings in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 45.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 25,226 shares of the company’s stock after acquiring an additional 7,886 shares during the period. Dimensional Fund Advisors LP owned 0.30% of Lisata Therapeutics worth $75,000 as of its most recent filing with the Securities and Exchange Commission. 8.94% of the stock is owned by institutional investors.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.